Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice

Journal of Clinical Investigation

Volumn 102, Issue 2, 1998, Pages 379-385

  Holvoet, Paul ^a   Danloy, Sophie ^a   Deridder, Els ^a   Lox, Marleen ^a   Bernar, Hilde ^a   Dhoest, Ann ^a   Collen, Désiré ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Apo AI; Apo AII; Atherosclerosis; Reverse cholesterol transport; Transgenic mice

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CARBOXY TERMINAL SEQUENCE; CHOLESTEROL TRANSPORT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; IMMUNOBLOTTING; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE;

EID: 0032527911     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI3038     Document Type: Article

References (28)

1. Gordon, D.J., and B.M. Rifkind. 1989. High-density lipoprotein - the clinical implications of recent studies. N. Engl. J. Med. 321:1311-1316.
2. Assmann, G., and H.B. Brewer, Jr. 1974. Lipid-protein interactions in high density lipoproteins. Proc. Natl. Acad. Sci. USA. 71:989-993.
3. Schaefer, E.J., W.H. Heaton, M.G. Wetzel, and H.B. Brewer, Jr. 1982. Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis. 2: 16-26.
4. 3. J. Biol. Chem. 264:6488-6494.
5. Rubin, E.M., B.Y. Ishida, S.M. Clift, and R.M. Krauss. 1991. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc. Natl. Acad. Sci. USA. 88:434-438.
6. Holvoet, P., S. Danloy, and D. Collen. 1997. Role of the carboxy-terminal domain of human apolipoprotein AI in high-density-lipoprotein metabolism - a study based on deletion and substitution variants in transgenic mice. Eur. J. Biochem. 245:642-647.
7. Hayek, T., Y. Ito, N. Azrolan, R.B. Verdery, K. Aalto Setala, A. Walsh, and J.L. Breslow. 1993. Dietary fat increases high density lipoprotein (HDL) levels both by increasing the transport rates and decreasing the fractional catabolic rates of HDL cholesterol ester and apolipoprotein (apo) A-I. Presentation of a new animal model and mechanistic studies in human apo A-I transgenic and control mice. J. Clin. Invest. 91:1665-1671.
8. Rubin, E.M., R.M. Krauss, E.A. Spangler, J.G. Verstuyft, and S.M. Clift. 1991. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 353:265-267.
9. Plump, A.S., J.D. Smith, T. Hayek, K. Aalto Setala, A. Walsh, J.G. Verstuyft, E.M. Rubin, and J.L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:343-353.
10. Zhang, S.H., R.L. Reddick, J.A. Piedrahita, and N. Maeda. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258:468-471.
11. Nakashima, Y., A.S. Plump, E.W. Raines, J.L. Breslow, and R. Ross. 1994. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 14:133-140.
12. Reddick, R.L., S.H. Zhang, and N. Maeda. 1994. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler. Thromb. 14:141-147. [published erratum appears on 14:839]
13. Paszty, C., N. Maeda, J. Verstuyft, and E.M. Rubin. 1994. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J. Clin. Invest. 94:899-903.
14. Plump, A.S., C.J. Scott, and J.L. Breslow. 1994. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA. 91:9607-9611.
15. Warden, C.H., C.C. Hedrick, J.H. Qiao, L.W. Castellani, and A.J. Lusis. 1993. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science 261:469-472. [published erratum appears on 262:164]
16. Schultz, J.R., E.L. Gong, M.R. McCall, A.V. Nichols, S.M. Clift, and E.M. Rubin. 1992. Expression of human apolipoprotein A-II and its effect on high density lipoproteins in transgenic mice. J. Biol. Chem. 267:21630-21636.
17. Marzal-Casacuberta, A., F. Blanco-Vaca, B.Y. Ishida, J. Julve Gil, J. Shen, S. Calvet-Marquez, F. Gonzalez-Sastre, and L. Chan. 1996. Functional lecithin:cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II. J. Biol. Chem. 271:6720-6728.
18. Schultz, J.R., J.G. Verstuyft, E.L. Gong, A.V. Nichols, and E.M. Rubin. 1993. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature. 365:762-764.
19. Holvoet, P., Z. Zhao, E. Deridder, A. Dhoest, and D. Collen. 1996. Effects of deletion of the carboxyl-terminal domain of ApoA-I or of its substitution with helices of ApoA-II on in vitro and in vivo lipoprotein association. J. Biol. Chem. 271:19395-19401.
20. Bradford, M.M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal. Biochem. 72:248-254.
21. Bolton, A.E., and W.M. Hunter. 1973. The use of antisera covalently coupled to agarose, cellulose and Sephadex in radioimmunoassay systems for proteins and haptens. Biochim. Biophys. Acta. 329:318-330.
22. Kleinberger, G., G. Heinzel, W. Druml, A. Laggner, and K. Lenz. 1987. Loading and maintenance dose for the determination of amino acid kinetics in plasma. Infusionsther. Klin. Ernahr. 1:40-44.
23. Tsuchiya, S., M. Yamabe, Y. Yamaguchi, Y. Kobayashi, T. Konno, and K. Tada. 1980. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer. 26:171-176.
24. Holvoet, P., G. Perez, H. Bernar, E. Brouwers, B. Vanloo, M. Rosseneu, and D. Collen. 1994. Stimulation with a monoclonal antibody (mAb4E4) of scavenger receptor-mediated uptake of chemically modified low density lipoproteins by THP-1-derived macrophages enhances foam cell generation. J. Clin. Invest. 93:89-98.
25. Atger, V., M. de la Llera Moya, M. Bamberger, O. Francone, P. Cosgrove, A. Tall, A. Walsh, N. Moatti, and G. Rothblat. 1995. Cholesterol efflux potential of sera from mice expressing human cholesteryl ester transfer protein and/or human apolipoprotein AI. J. Clin. Invest. 96:2613-2622.
26. Francone, O.L., L. Royer, and M. Haghpassand. 1996. Increased prebeta-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes. J. Lipid Res. 37:1268-1277.
27. Castro, G., L.P. Nihoul, C. Dengremont, C. de Geitere, B. Delfly, A. Tailleux, C. Fievet, N. Duverger, P. Denefle, J.C. Fruchart, and E.M. Rubin. 1997. Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and prebeta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport. Biochemistry. 36:2243-2249.
28. Gong, E.L., L.J. Stolzfus, C.M. Brion, D. Murugesh, and E.M. Rubin. 1996. Contrasting in vivo effects of murine and human apolipoprotein A-II. J. Biol. Chem. 271:5984-5987.